These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 31187861)

  • 21. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
    Harrison PT; Vyse S; Huang PH
    Semin Cancer Biol; 2020 Apr; 61():167-179. PubMed ID: 31562956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.
    Jiang Y; Fang X; Xiang Y; Fang T; Liu J; Lu K
    Curr Oncol; 2023 May; 30(6):5337-5349. PubMed ID: 37366888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report.
    Xu F; Xia ML; Pan HY; Pan JW; Shen YH
    World J Clin Cases; 2022 Jun; 10(17):5916-5922. PubMed ID: 35979118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report.
    Van Acker L; Stevens D; Vermaelen K; Surmont V
    J Med Case Rep; 2021 Nov; 15(1):562. PubMed ID: 34809713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report.
    Long X; Qin T; Lin J
    Onco Targets Ther; 2020; 13():10689-10692. PubMed ID: 33116645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
    Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
    Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
    Shi Y; Wang M
    Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
    Ibrahim U; Saqib A; Atallah JP
    Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
    Zeng L; Zhang Y; Yang N
    J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
    [No Abstract]   [Full Text] [Related]  

  • 30. Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.
    Jelli B; Taton O; D'Haene N; Remmelink M; Mekinda Z
    Eur J Case Rep Intern Med; 2021; 8(8):002749. PubMed ID: 34527619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.
    An N; Wang H; Zhu H; Yan W; Jing W; Kong L; Zhang Y; Yu J
    Onco Targets Ther; 2019; 12():7399-7404. PubMed ID: 31686847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report.
    Valcárcel S; Villanueva N; Álvarez C; Esteban E
    Anticancer Drugs; 2024 Aug; 35(7):638-640. PubMed ID: 38513159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
    Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.